The Irish Haemophilia Society (IHS) continues to play a vital role in supporting people with haemophilia and related bleeding disorders worldwide, with a particular focus on individuals living in developing and emerging countries. For many people in these regions, daily life with a bleeding disorder remains extremely challenging. Too many still do not survive into adulthood, while others have access to care and treatment that is no better — and in some cases worse — than what was available in Ireland more than four decades ago. The IHS remains firmly committed to addressing these inequalities and improving global outcomes for people with bleeding disorders.

The IHS actively supports the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) Programme, which aims to identify, diagnose, and treat tens of thousands of previously undiagnosed people with haemophilia across multiple countries over a ten-year period. We work in close partnership with the WFH on its humanitarian aid programme and have participated in several successful Twinning Programmes, which focus on building sustainable capacity and long-term care in partner countries. In addition, the IHS contributes to the global haemophilia community through active involvement in the WFH’s Product Safety Committee, Executive Committee, and Psychosocial Committee. At a European level, the IHS plays a role within the European Haemophilia Consortium (EHC), contributing to their work on health technology assessment, health economics, patient research, and EU regulatory and policy initiatives.